| scholarly article | Q13442814 |
| P2093 | author name string | Takeshi Shimosato | |
| Suguru Shigemori | |||
| P2860 | cites work | Heme oxygenase and heme degradation | Q21710702 |
| Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 | ||
| Interleukin-10 and the interleukin-10 receptor | Q24290912 | ||
| The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor | Q24309259 | ||
| Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide | Q24535758 | ||
| Common variants at five new loci associated with early-onset inflammatory bowel disease | Q24600801 | ||
| The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403 | Q24618705 | ||
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes | Q26786083 | ||
| Modulation of Intestinal TLR4-Inflammatory Signaling Pathways by Probiotic Microorganisms: Lessons Learned from Lactobacillus jensenii TL2937 | Q26992250 | ||
| Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case | Q27028100 | ||
| Immunoregulatory Effects Triggered by Lactic Acid Bacteria Exopolysaccharides: New Insights into Molecular Interactions with Host Cells | Q28078715 | ||
| Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models | Q28083627 | ||
| Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 | Q28179431 | ||
| Lactobacillus rhamnosus GG and Streptococcus thermophilus induce suppressor of cytokine signalling 3 (SOCS3) gene expression directly and indirectly via interleukin-10 in human primary macrophages. | Q54592118 | ||
| World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. | Q55056247 | ||
| Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo | Q57079498 | ||
| Infant colitis—it's in the genes | Q57522226 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Bifidobacterium infantis35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells | Q59879275 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis | Q60691022 | ||
| Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice | Q62061832 | ||
| Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients | Q73157927 | ||
| Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Q73837821 | ||
| Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase | Q79317636 | ||
| Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis | Q80641555 | ||
| Identification of a potent immunostimulatory oligodeoxynucleotide from Streptococcus thermophilus lacZ | Q82936796 | ||
| Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice | Q82939811 | ||
| CpG oligodeoxynucleotides induce strong up-regulation of interleukin 33 via Toll-like receptor 9 | Q83009701 | ||
| Lactobacillus casei secreting alpha-MSH induces the therapeutic effect on DSS-induced acute colitis in Balb/c Mice | Q83161673 | ||
| Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis | Q83220790 | ||
| Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum | Q83309521 | ||
| Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis | Q83902074 | ||
| The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
| Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ | Q84878848 | ||
| Milk fermented with a 15-lipoxygenase-1-producing Lactococcus lactis alleviates symptoms of colitis in a murine model | Q85959774 | ||
| Oral Bifidobacterium longum expressing alpha-melanocyte-stimulating hormone to fight experimental colitis | Q86919224 | ||
| Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. | Q54486654 | ||
| Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic | Q28241661 | ||
| Review article: Infliximab therapy for inflammatory bowel disease--seven years on | Q28294134 | ||
| A helminth immunomodulator exploits host signaling events to regulate cytokine production in macrophages | Q28476708 | ||
| Interleukin-10-deficient mice develop chronic enterocolitis | Q29547881 | ||
| Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein | Q33293246 | ||
| Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity | Q33309955 | ||
| Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation | Q33356616 | ||
| The treatment-naive microbiome in new-onset Crohn's disease | Q33762817 | ||
| Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases | Q33785337 | ||
| Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria | Q33787825 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Survival, physiology, and lysis of Lactococcus lactis in the digestive tract | Q33985970 | ||
| Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes | Q34241570 | ||
| Heme oxygenase-1 ameliorates dextran sulfate sodium-induced acute murine colitis by regulating Th17/Treg cell balance | Q34244988 | ||
| Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. | Q34415570 | ||
| A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease | Q34529230 | ||
| Pharmacological and clinical aspects of heme oxygenase | Q34759206 | ||
| Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies | Q34992075 | ||
| Intestinal bacteria and ulcerative colitis | Q35105588 | ||
| Immunobiotics and the probiotic evolution | Q35192433 | ||
| Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination | Q35193105 | ||
| Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. | Q35233808 | ||
| Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells | Q35381281 | ||
| Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. | Q35595783 | ||
| Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. | Q35653282 | ||
| Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner | Q35719834 | ||
| Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp. cremoris MG1363. | Q35759658 | ||
| Immunopathogenesis of IBD: current state of the art. | Q35857951 | ||
| Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice | Q35942422 | ||
| Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon | Q36000703 | ||
| Portrait of an immunoregulatory Bifidobacterium | Q36187698 | ||
| Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice | Q36317250 | ||
| Probiotics and the gut microbiota in intestinal health and disease | Q36567134 | ||
| Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier | Q36971362 | ||
| Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut | Q37097658 | ||
| Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria | Q37111626 | ||
| Inflammatory bowel disease and mutations affecting the interleukin-10 receptor | Q37454505 | ||
| Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. | Q37545831 | ||
| Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice | Q37577227 | ||
| Immunosuppressive therapies for inflammatory bowel disease | Q37660661 | ||
| Mucosal vaccination and therapy with genetically modified lactic acid bacteria | Q37963078 | ||
| Modulation of Respiratory TLR3-Anti-Viral Response by Probiotic Microorganisms: Lessons Learned from Lactobacillus rhamnosus CRL1505. | Q38214645 | ||
| Regulation of toll-like receptors-mediated inflammation by immunobiotics in bovine intestinal epitheliocytes: role of signaling pathways and negative regulators | Q38250324 | ||
| IL-6 as a keystone cytokine in health and disease | Q38433045 | ||
| Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis | Q38836734 | ||
| Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application | Q38957782 | ||
| Cytokine profile and induction of T helper type 17 and regulatory T cells by human peripheral mononuclear cells after microbial exposure. | Q39413865 | ||
| Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells | Q39613832 | ||
| Parasite-Specific Immunomodulatory Functions of Filarial Cystatin | Q39746044 | ||
| Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis | Q39793093 | ||
| Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis | Q40322591 | ||
| A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation | Q40569121 | ||
| Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis | Q40685749 | ||
| Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model | Q40982304 | ||
| Interleukin-10 gene-carrying bifidobacteria ameliorate murine ulcerative colitis by regulating regulatory T cell/T helper 17 cell pathway | Q41763748 | ||
| rBet v 1 immunotherapy of sensitized mice with Streptococcus thermophilus as vehicle and adjuvant. | Q41822453 | ||
| Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci | Q41981077 | ||
| Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea | Q42114162 | ||
| Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice | Q42414101 | ||
| Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. | Q42614290 | ||
| Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide | Q42785654 | ||
| A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages | Q43833485 | ||
| Effect of recombinant Lactobacillus casei expressing interleukin-10 in dextran sulfate sodium-induced colitis mice | Q43907875 | ||
| Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis | Q43945848 | ||
| Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy | Q44656894 | ||
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
| Recombinant probiotic therapy in experimental colitis in mice | Q45885340 | ||
| Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
| Superoxide dismutase recombinant Lactobacillus fermentum ameliorates intestinal oxidative stress through inhibiting NF-κB activation in a trinitrobenzene sulphonic acid-induced colitis mouse model | Q46938089 | ||
| Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88. | Q47729248 | ||
| A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease | Q47839326 | ||
| Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice | Q48017796 | ||
| Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 | ||
| Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. | Q49114588 | ||
| Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis | Q49127094 | ||
| Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice | Q49134239 | ||
| Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial | Q50436362 | ||
| Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model. | Q51108500 | ||
| Secretion of an immunoreactive single-chain variable fragment antibody against mouse interleukin 6 by Lactococcus lactis. | Q51141275 | ||
| Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. | Q51479359 | ||
| Survival of lactococci during passage through mouse digestive tract. | Q51720681 | ||
| A nematode immunomodulator suppresses grass pollen-specific allergic responses by controlling excessive Th2 inflammation. | Q52886006 | ||
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 22 | |
| P577 | publication date | 2017-01-25 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases | |
| P478 | volume | 8 |
| Q58780488 | Aberrantly Expressed Genes and miRNAs in Slow Transit Constipation Based on RNA-Seq Analysis |
| Q90701028 | Biology and therapeutic potential of interleukin-10 |
| Q59791570 | Delivery of IL-35 by Ameliorates Collagen-Induced Arthritis in Mice |
| Q93090557 | Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases |
| Q100316274 | Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice |
| Q91559900 | Probiotics ingestion prevents HDAC11-induced DEC205+ dendritic cell dysfunction in night shift nurses |
| Q46307319 | Recombinant Mouse Osteocalcin Secreted by Lactococcus lactis Promotes Glucagon-Like Peptide-1 Induction in STC-1 Cells. |
Search more.